A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
← catalyst calendarNCT06143891 · readout in 772 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
260estimated
Sites
151
Countries
Argentina, Australia, Austria +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-23 | actual | When the study began enrolling |
| Primary completion | 2028-09-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-29 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Graft Versus Host Disease
Interventions
- Drug: Belumosudil — also filed as SAR445761/ KD025, REZUROCK
- Drug: Placebo
- Drug: Prednisone
- Drug: Prednisolone
Primary outcome
what the primary-completion date above is the date OFEvent-Free Survival (EFS)
measured Until the end of the study (up to 2.5 years since first patient in).
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed